PharmGKB: The Pharmacogenomics Knowledge Base

Evidence of Relationships Between NQO1 and epirubicin

From Publications

Relationship Evidence Details
  • CO
  •   
  •   
  • FA
  • GN
NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet. 2008. Fagerholm Rainer, et al. PMID: 18511948. View

From Variant Annotations

Curated Annotations (Curated Annotation)

  1. rs1800566 at chr16:68302646
    This homozygous variant predicts poor survival among two independent series of women with breast cancer. This effect is particularly evident after anthracycline-based adjuvant chemotherapy with epirubicin and in p53-aberrant tumors.
    Variant Name:
    NQO1:c.558C>T; NQO1(*)2
    Related Drugs:
    epirubicin
    Related Diseases:
    Breast Neoplasms
    Evidence:
    PMID:18511948
Variant names are different names that have been used in the literature and other resources to refer to the same variant.
PharmGKB® is a registered trademark of HHS and is financially supported by NIH/NIGMS. It is managed at Stanford University (GM61374).
©2001-2010 PharmGKB.